How would you approach Grade 2-3 rash due to erlotinib for a patient with metastatic EGFR mutated lung adenocarcinoma that is well controlled for > 5 years and NED by PET?  

This is a favorable challenge to approach given the complete response on erlotinib for more than 5 years. In addition to treating the current grade 2-3 rash with a 7-10 day interruption of erlotinib, a short course of oral steroids, and aggressive local skin treatment, I would approach based on seve...